

**Amendments to the Claims:**

This listing will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1 and 2 (cancelled)

Claim 3 (Currently amended): A purified peptide having anti-angiogenic functionality ~~of the~~  
structure based on an amino acid sequence:

~~Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp~~ SEQ ID NO: 4

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus  
(on the right);

wherein the ~~peptide sequence corresponds to the fourth peptide of peptides of GeneBank~~  
~~LocusID:4018 which are separated by cysteine units,~~  
and wherein at least one amino acid of said peptide is in a D-form.

Claim 4: A pharmaceutical composition comprising said peptide of claim 3.

Claim 5: (Currently amended): A purified peptide having anti-angiogenic functionality ~~of the~~  
structure based on an amino acid sequence:

~~Arg Asn Pro Asp Gly Asp Ile Asn Gly Pro Trp~~ SEQ ID NO: 4

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein the ~~peptide sequence corresponds to the fourth peptide of peptides of GeneBank~~  
~~LocusID:4018~~ which are separated by cysteine units, wherein one amino acid is removed, replaced,  
or added to said peptide to form a new molecule

and wherein either a C-terminal protecting group or an N-terminal protecting group is removed from the peptide.

Claim 6 (Currently amended): A purified pharmaceutical product comprising a peptide having anti-angiogenic functionality of the structure based on an amino acid sequence:

~~Arg Asn Pro Asp Gly Asp Ile Asn Gly Pro Trp~~ SEQ ID NO: 4

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein the ~~peptide sequence corresponds to the fourth peptide of peptides of GeneBank~~ ~~LocusID:~~  
~~4018~~ which are separated by cysteine units,

and wherein either a C-terminal protecting group or an N-terminal protecting group is removed from the peptide.

Appl. No. 09/927,006  
Response. Dated April 28, 2006  
Reply to Office Action of November 28, 2006

**Claim 7:** The purified peptide according to claim 3, wherein either a C-terminal protecting group or an N-terminal protecting group is removed from the peptide.

**Claim 8:** A pharmaceutical product comprising said peptide of claim 7.

**Claims 9-12 (cancelled)**